We have located open access text paper links.
An Evaluation of the Efficacy and Safety of Timolol Maleate 0.5% Microdrops Administered with the Nanodropper®.
Ophthalmology 2024 March 15
OBJECTIVE OR PURPOSE: Examine if 12.5 μL timolol maleate 0.5% microdrops dispensed with the Nanodropper® Adaptor provide non-inferior intraocular pressure (IOP) reduction compared to conventional, 28 μL drops in open-angle glaucoma (OAG) and ocular hypertension (OHT) patients.
DESIGN: Prospective, non-inferiority, parallel, multicenter, single-masked, active-controlled, randomized trial.
SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Treatment-naïve subjects that were recently diagnosed with OAG/OHT at the Aravind Eye Care System.
METHODS, INTERVENTION, OR TESTING: Both eyes of subjects received either one commercially available drop or one microdrop of timolol maleate 0.5%. We measured IOP, resting heart rate (HR), and blood pressure (BP) at baseline and 1, 2, 5, and 8 hours after timolol administration.
MAIN OUTCOME MEASURES: IOP was the primary outcome measure. Secondary outcomes were resting HR, systolic BP (sBP), and diastolic BP (dBP).
RESULTS: Adaptor-mediated microdrops and conventional drops of timolol significantly decreased IOP compared to baseline at all timepoints. Non-inferiority was established at three of four timepoints. HR decreases with Nanodropper were ∼3 bpm less than with conventional drops.
CONCLUSIONS: Timolol microdrops appear to be as effective in ocular hypotensive action as conventional drops with a slightly lesser effect on resting HR and BP.
DESIGN: Prospective, non-inferiority, parallel, multicenter, single-masked, active-controlled, randomized trial.
SUBJECTS, PARTICIPANTS, AND/OR CONTROLS: Treatment-naïve subjects that were recently diagnosed with OAG/OHT at the Aravind Eye Care System.
METHODS, INTERVENTION, OR TESTING: Both eyes of subjects received either one commercially available drop or one microdrop of timolol maleate 0.5%. We measured IOP, resting heart rate (HR), and blood pressure (BP) at baseline and 1, 2, 5, and 8 hours after timolol administration.
MAIN OUTCOME MEASURES: IOP was the primary outcome measure. Secondary outcomes were resting HR, systolic BP (sBP), and diastolic BP (dBP).
RESULTS: Adaptor-mediated microdrops and conventional drops of timolol significantly decreased IOP compared to baseline at all timepoints. Non-inferiority was established at three of four timepoints. HR decreases with Nanodropper were ∼3 bpm less than with conventional drops.
CONCLUSIONS: Timolol microdrops appear to be as effective in ocular hypotensive action as conventional drops with a slightly lesser effect on resting HR and BP.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app